NCT07024316: An ongoing trial by Atlas Molecular Pharma
This trial is ongoing. It must report results 2 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07024316 |
|---|---|
| Title | A Phase I-II, N-of-1, Open-Label, Prospective Study to Evaluate the Efficacy and Safety of ATL-001 in Adult Participants With Congenital Erythropoietic Porphyria (CEP) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 1, 2025 |
| Completion date | Aug. 1, 2027 |
| Required reporting date | July 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |